| Primary |
| Drug Use For Unknown Indication |
15.7% |
| Prophylaxis |
11.3% |
| Pseudomonas Infection |
8.4% |
| Infection Prophylaxis |
6.4% |
| Infection |
6.1% |
| Sepsis |
6.1% |
| Product Used For Unknown Indication |
4.9% |
| Antibiotic Prophylaxis |
4.7% |
| Drug Exposure During Pregnancy |
4.7% |
| Bacteraemia |
4.4% |
| Endocarditis |
4.4% |
| Urinary Tract Infection |
3.2% |
| Endophthalmitis |
2.9% |
| Pneumonia |
2.9% |
| Staphylococcal Infection |
2.9% |
| Cystic Fibrosis |
2.3% |
| Osteomyelitis |
2.3% |
| Pain |
2.3% |
| Abscess Limb |
2.0% |
| Lower Respiratory Tract Infection |
2.0% |
|
| Renal Failure Acute |
15.7% |
| Renal Tubular Necrosis |
9.7% |
| Vestibular Disorder |
9.0% |
| Renal Failure |
8.2% |
| Application Site Scab |
7.5% |
| Application Site Vesicles |
6.7% |
| Tetany |
4.5% |
| Vertigo |
4.5% |
| Renal Impairment |
3.7% |
| Tinnitus |
3.7% |
| Ocular Hyperaemia |
3.0% |
| Ototoxicity |
3.0% |
| Pyrexia |
3.0% |
| Somnolence |
3.0% |
| Toxic Epidermal Necrolysis |
3.0% |
| Vomiting |
3.0% |
| Application Site Erythema |
2.2% |
| Blood Creatinine Increased |
2.2% |
| Cardio-respiratory Arrest |
2.2% |
| Cerebrovascular Accident |
2.2% |
|
| Secondary |
| Product Used For Unknown Indication |
33.1% |
| Drug Use For Unknown Indication |
14.1% |
| Endocarditis |
6.4% |
| Prophylaxis |
5.4% |
| Infection |
5.3% |
| Sepsis |
4.0% |
| Hypertension |
3.1% |
| Pain |
3.0% |
| Antibiotic Therapy |
3.0% |
| Pseudomonas Infection |
2.9% |
| Pneumonia |
2.8% |
| Staphylococcal Infection |
2.7% |
| Pyrexia |
2.3% |
| Antibiotic Prophylaxis |
1.9% |
| Urinary Tract Infection |
1.8% |
| Keratitis Fungal |
1.8% |
| Drug Exposure During Pregnancy |
1.7% |
| Abdominal Infection |
1.6% |
| Bronchopneumonia |
1.6% |
| Klebsiella Infection |
1.5% |
|
| Renal Failure Acute |
24.7% |
| Toxic Epidermal Necrolysis |
8.2% |
| Myocardial Infarction |
6.1% |
| Premature Baby |
5.1% |
| Renal Tubular Necrosis |
5.1% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
4.8% |
| Neutropenia |
4.0% |
| Renal Failure |
4.0% |
| Treatment Failure |
4.0% |
| Renal Impairment |
3.7% |
| Vomiting |
3.7% |
| Pyrexia |
3.2% |
| Thrombocytopenia |
3.2% |
| Toxic Skin Eruption |
3.2% |
| Tubulointerstitial Nephritis |
3.2% |
| Drug Hypersensitivity |
2.9% |
| Tinnitus |
2.9% |
| Anaphylactic Reaction |
2.7% |
| Death |
2.7% |
| Drug Ineffective |
2.7% |
|
| Concomitant |
| Product Used For Unknown Indication |
42.5% |
| Drug Use For Unknown Indication |
26.0% |
| Prophylaxis |
3.5% |
| Endocarditis |
2.7% |
| Infection |
2.6% |
| Pain |
2.5% |
| Sepsis |
2.3% |
| Acute Myeloid Leukaemia |
2.2% |
| Hypertension |
2.0% |
| Pneumonia |
1.9% |
| Peritoneal Dialysis |
1.8% |
| Nausea |
1.6% |
| Pyrexia |
1.4% |
| Constipation |
1.3% |
| Diabetes Mellitus |
1.3% |
| Sarcoma Metastatic |
1.0% |
| Staphylococcal Infection |
0.9% |
| Adverse Event |
0.9% |
| Hiv Infection |
0.9% |
| Urinary Tract Infection |
0.9% |
|
| Vomiting |
15.6% |
| Sepsis |
9.2% |
| Thrombocytopenia |
8.7% |
| Renal Failure Acute |
7.3% |
| Pyrexia |
4.7% |
| Weight Decreased |
4.5% |
| White Blood Cell Count Decreased |
4.5% |
| Rhabdomyolysis |
4.4% |
| Tachycardia |
4.4% |
| Toxic Epidermal Necrolysis |
3.9% |
| Death |
3.8% |
| Renal Failure |
3.8% |
| Injury |
3.4% |
| Septic Shock |
3.4% |
| Respiratory Failure |
3.3% |
| Urinary Tract Infection |
3.3% |
| Urticaria |
3.2% |
| Hypotension |
3.0% |
| Pulmonary Haemorrhage |
2.9% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
2.8% |
|
| Interacting |
| Bronchopulmonary Aspergillosis |
38.1% |
| Pneumonia |
19.0% |
| Prophylaxis |
11.9% |
| Contraception |
9.5% |
| Aspergillosis |
4.8% |
| Product Used For Unknown Indication |
4.8% |
| Bacteraemia |
2.4% |
| Endocarditis |
2.4% |
| Schizophrenia |
2.4% |
| Suicide Attempt |
2.4% |
| Aplasia |
1.2% |
| Thrombosis Prophylaxis |
1.2% |
|
| Drug Interaction |
12.9% |
| Renal Failure |
12.9% |
| Dehydration |
9.7% |
| Renal Failure Acute |
9.7% |
| Unintended Pregnancy |
9.7% |
| Immunosuppressant Drug Level Decreased |
6.5% |
| International Normalised Ratio Increased |
6.5% |
| Overdose |
6.5% |
| Spina Bifida Cystica |
6.5% |
| White Blood Cell Count Decreased |
6.5% |
| Blood Urea Increased |
3.2% |
| Drug Ineffective |
3.2% |
| Hypersensitivity |
3.2% |
| Respiratory Distress |
3.2% |
|
